Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in epidermal growth factor receptor-2-negative, mesenchymal-epithelial transition-positive gastroesophageal adenocarcinoma: Is it a real failure?

Gastric cancer (GC) is the sixth most common cancer worldwide and the fourth leading cause of cancer-related deaths. The median overall survival is between 8–16 months but varies for different geographical locations. Because of its asymptomatic nature, GC is usually diagnosed at an advanced stage, mostly with metastasis (1,2).